Sep 17, 2025 07:13AM X4 Pharmaceuticals cuts workforce 50% to save $13 million annually

Sep 10, 2025 04:21PM X4 Pharmaceuticals (XFOR) files for 59.89M share offering by selling stockholders

Aug 29, 2025 07:17AM X4 Pharmaceuticals (XFOR) PT Lowered to $9 at Stifel

Aug 25, 2025 08:16AM X4 Pharmaceuticals directors resign, board appointments made

Aug 13, 2025 06:55AM X4 Pharmaceuticals (XFOR) PT Lowered to $3.50 at H.C. Wainwright

Aug 12, 2025 03:38PM X4 Pharmaceuticals (XFOR) Halted, News Pending

Aug 12, 2025 07:01AM X4 Pharmaceuticals secures $60 million financing, replaces CEO and CFO

Jun 16, 2025 08:02AM X4 Pharmaceuticals (XFOR) Presents Positive Phase 2 Chronic Neutropenia Trial Data

Jun 10, 2025 08:02AM X4 Pharmaceuticals (XFOR) Granted FDA Fast Track Designation for Mavorixafor

May 2, 2025 07:28AM X4 Pharmaceuticals (XFOR) PT Raised to $7 at H.C. Wainwright

May 1, 2025 06:30AM X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 16c

Apr 24, 2025 08:01AM X4 Pharmaceuticals (XFOR) Announces Reverse Stock Split

Mar 27, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)

Mar 26, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on X4 Pharmaceuticals (XFOR)

Mar 25, 2025 02:25PM X4 Pharmaceuticals (XFOR) PT Lowered to $3 at Stifel

Mar 25, 2025 10:56AM Brookline Capital Markets Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)

Mar 25, 2025 06:10AM X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 4c

Feb 19, 2025 07:35AM X4 Pharmaceuticals (XFOR) and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI

Feb 6, 2025 07:35AM X4 Pharmaceuticals (XFOR) Announces Strategic Restructuring

Jan 29, 2025 02:48PM X4 Pharmaceuticals (XFOR) said approached by Cheisi about takeover - source

Jan 24, 2025 07:38AM X4 Pharmaceuticals (XFOR) Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025 07:35AM X4 Pharmaceuticals (XFOR) and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024 07:00AM X4 Pharmaceuticals (XFOR) PT Lowered to $1.50 at H.C. Wainwright

Nov 13, 2024 04:00PM X4 Pharmaceuticals (XFOR) PT Lowered to $4 at Stifel

Nov 13, 2024 06:24AM X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

Nov 13, 2024 06:07AM X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 1c

Aug 8, 2024 06:08AM X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 46c

Aug 7, 2024 09:54AM Increasing unusual option volume: XFOR LUMN RYAM DT REAL SHLS LAZR ACAD

Jun 28, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)

Jun 27, 2024 04:00PM Brookline Capital Markets Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)

Jun 27, 2024 03:49PM Stifel on X4 Pharmaceuticals (XFOR): 'today’s disclosure significantly de-risks the now enrolling P3 4WARD trial'

Jun 27, 2024 06:30AM X4 Pharmaceuticals (XFOR) Reports Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor